Didanosine

Didanosine

SCHEMBL284944

O=P(O)(O)O.O=c1[nH]cnc2c1ncn2[C@H]1CC[C@@H](CO)O1

nearest known ligand 0.91

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

pol

The experimentally established mechanism targets of Didanosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.91
LMNA P02545 1/20 0.91
ALB P02768 1/20 0.91
MAPK1 P28482 1/20 0.91
TDP1 Q9NUW8 1/20 0.49
CYP1A2 P05177 1/20 0.48
P2RX3 P56373 1/20 0.48
HPRT1 P00492 3/20 0.47
ADORA3 P0DMS8 3/20 0.46
TYMP P19971 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Didanosine SCHEMBL887093 1.00 ALDH1A1 (0.91) ALDH1A1LMNAALBMAPK1TDP1
Didanosine SCHEMBL16695885 0.95 ALDH1A1 (1.00) ALDH1A1LMNAALBMAPK1TDP1
Didanosine SCHEMBL16695888 0.95 ALDH1A1 (1.00) ALDH1A1LMNAALBMAPK1TDP1
Didanosine SCHEMBL3363 0.95 ALDH1A1 (1.00) ALDH1A1LMNAALBMAPK1TDP1
Didanosine SCHEMBL1674335 0.95 ALDH1A1 (1.00) ALDH1A1LMNAALBMAPK1TDP1
Didanosine SCHEMBL5021456 0.95 ALDH1A1 (1.00) ALDH1A1LMNAALBMAPK1TDP1
Didanosine SCHEMBL16695883 0.95 ALDH1A1 (1.00) ALDH1A1LMNAALBMAPK1TDP1
Didanosine SCHEMBL7787270 0.94 ALDH1A1 (0.84) ALDH1A1LMNAALBMAPK1TDP1
Didanosine SCHEMBL7904473 0.93 ALDH1A1 (0.95) ALDH1A1LMNAALBMAPK1TDP1
Didanosine SCHEMBL2327408 0.88 ALDH1A1 (0.85) ALDH1A1LMNAALBMAPK1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2428201-A1 Oral administration of nucleoside monophosphates Merck Serono S.A. (CH) 2012-03-14 EP claimed
US-20060105375-A1 Bioretrosynthetic methods for preparing products and compositions related thereto VANDERBILT UNIVERSITY 2006-05-18 US claimed
WO-2006044918-A2 COMPOUNDS USEFUL AS SUBSTRATES FOR ENZYMES THAT REVERSE NUCLEOTIDYLYLATED PEPTIDE AND PROTEIN MODIFICATIONS AND METHODS FOR PRODUCTION AND USES THEREOF TRUSTEES OF DARTMOUTH COLLEGE (US) 2006-04-27 WO claimed
EP-2428201-A1 Oral administration of nucleoside monophosphates Merck Serono S.A. (CH) 2012-03-14 EP disclosed
US-20060105375-A1 Bioretrosynthetic methods for preparing products and compositions related thereto VANDERBILT UNIVERSITY 2006-05-18 US disclosed
WO-2006044918-A2 COMPOUNDS USEFUL AS SUBSTRATES FOR ENZYMES THAT REVERSE NUCLEOTIDYLYLATED PEPTIDE AND PROTEIN MODIFICATIONS AND METHODS FOR PRODUCTION AND USES THEREOF TRUSTEES OF DARTMOUTH COLLEGE (US) 2006-04-27 WO disclosed